Thank You for Joining Us Virtually

September 23, 2020

2020 Healthcare-Focused Sohn Investment Conference

In Partnership With

In Support Of


Sign up to receive the latest on The Sohn Investment Conference in Partnership with CNBC.

Dear Friends of Sohn,

The year 2020 marks the 25th anniversary of the Sohn Investment Conference with over $90 million donated to cure and treat pediatric cancer. We are grateful for the contributions from the Sohn community to help achieve this milestone.

On September 23rd we hosted a healthcare-focused virtual Sohn. Over the course of 90 minutes, speakers delivered cutting edge and actionable healthcare investment insights, all in support of fighting COVID-19.

All proceeds of the September 23rd gathering support Rockefeller University’s Dr. Michel Nussenzweig, who is developing a novel therapy for COVID-19. Dr. Nussenzweig’s potent monoclonal antibodies against SARS-CoV-2 will enter clinical trials this fall. He is using an approach he pioneered several years ago discovering and harnessing neutralizing antibodies against HIV. Gilead Sciences recently acquired the license to develop this new HIV antibody therapy. The Nussenzweig lab continues to spearhead the design of effective therapies against other known and emerging global infectious diseases.

Founded in 1901, Rockefeller is the world’s leading biomedical research university, drawing top scientists and graduate students from around the world in pursuit of one mission: to conduct science for the benefit of humanity.

We thank you for your continued support of our cause.

2020 Healthcare-Focused Sohn Investment Conference Chairs

2020 Healthcare-Focused Sohn Investment Conference Speakers

Thank You To Our Sponsors


East Rock Capital

Will & Kacie Snellings



Cormorant Asset Management
ECOr1 Capital


boxer capital

Josh Wolfe & Lauren Taylor Wolfe


RBC Captial Markets

Daniel Nir

Pointer Management


Cavalry Fund

Crescent Rock Capital Management, LP

Crestone Capital, LLC

Gaute Ulltveit-Moe

Lineage Logistics